Recent news and posts
Extended reimbursement for next-generation sequencing (NGS) in Belgium
Molecular biology tests by next-generation sequencing (NGS) in oncology and hemato-oncology are temporarily reimbursed as a pilot under a specific agreement (Convention) with the National Institute for Health and Disability Insurance (INAMI-RIZIV) from 2019.
On July 1, 2023, the Convention was extended for one year. The lists with eligible clinical indications connected to specific biomarkers (separately for solid and hematological tumors) were updated as well.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.